Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 18/20 | 0.56 |
| ▸ | CCR3 | P51677 | 18/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5372445 | 0.99 | HRH1 (0.55) | HRH1CCR3KCNH2KDM4EALDH1A1 | |
| SCHEMBL5190493 | 0.93 | HRH1 (0.67) | HRH1CCR3KCNH2 | |
| SCHEMBL5194584 | 0.90 | HRH1 (0.66) | HRH1CCR3KCNH2 | |
| SCHEMBL5194600 | 0.89 | HRH1 (0.64) | HRH1CCR3KCNH2 | |
| SCHEMBL5363961 | 0.87 | CCR3 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL5102629 | 0.85 | HRH1 (0.61) | HRH1CCR3KCNH2KDM4EALDH1A1 | |
| SCHEMBL5102799 | 0.82 | HRH1 (0.59) | HRH1CCR3KCNH2KDM4E | |
| SCHEMBL5657070 | 0.82 | CCR3 (0.67) | HRH1CCR3KCNH2 | |
| SCHEMBL13703552 | 0.80 | FFAR4 (0.56) | — | |
| SCHEMBL5369447 | 0.79 | HRH1 (0.56) | HRH1CCR3KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265227-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-09-04 | — | — | US | disclosed |
| US-20040176411-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| EP-1412330-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003018556-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176411-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCRL2, CCR1, CCR3 | HRH1 27/4885CCR3 3/4885KCNH2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.